Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 -0.44%79 3-Year ROIIC % is 20.02 as of Dec. 2025, which is 27% above its 10-year median of 15.73. GuruFocus rates SHSE:605116 with a GF Score™ of 79/100 and a GF Value™ of ¥29.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,315 Biotechnology companies, Aurisco Pharmaceutical Co ranks better than 64.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Aurisco Pharmaceutical Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 20.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aurisco Pharmaceutical Co's 3-Year ROIIC % or its related term are showing as below:
SHSE:605116's 3-Year ROIIC % is ranked better than 64.79% of 1315
companies
in the Biotechnology industry
Industry Median: -4.4
vs SHSE:605116: 20.02
Aurisco Pharmaceutical Co (SHSE:605116) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aurisco Pharmaceutical Co 3-Year ROIIC % Related Terms
Aurisco Pharmaceutical Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aurisco Pharmaceutical Co (SHSE:605116) has a 3-Year ROIIC % of 20.02 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 27% above median its historical median of 15.73. Over the past decade, Aurisco Pharmaceutical Co's 3-Year ROIIC % has ranged from 6.98 to 33.55. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #463 out of 1315 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Aurisco Pharmaceutical Co's 3-Year ROIIC % too high?
Aurisco Pharmaceutical Co's current 3-Year ROIIC % of 20.02 is 27% above median its 10-year median of 15.73. Over the past 10 years, this metric has ranged from a low of 6.98 to a high of 33.55. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #463 out of 1315 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #463 out of 1315 companies for 3-Year ROIIC %. This puts Aurisco Pharmaceutical Co in the upper half of its industry. Historically, Aurisco Pharmaceutical Co's own 3-Year ROIIC % has ranged from 6.98 to 33.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aurisco Pharmaceutical Co and its competitors. Aurisco Pharmaceutical Co's current 3-Year ROIIC % is 20.02, which is 27% above median its own 10-year median of 15.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥29.34, compared to a current price of ¥20.50 — trading 30.1% below its estimated fair value. The current 3-Year ROIIC % is 20.02, which is 27% above median its 10-year median of 15.73. Aurisco Pharmaceutical Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current 3-Year ROIIC % is 20.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥20.50 is trading 30.1% below its estimated GF Value™ of ¥29.34.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
3-Year ROIIC %: 20.02 (27% above median its 10-year median of 15.73)
GF Value™: ¥29.34 vs. price of ¥20.50 (30.1% below fair value)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
79GF Score
Get the complete analysis for SHSE:605116
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
